First approved in 2017, Imfinzi was previously available in the U.S. as a combination therapy for treating metastatic NSCLC. More on AstraZeneca AstraZeneca PLC (AZN) Q2 2024 Earnings Call Transcript ...

Olivier Nataf, Head of US Oncology, said, “This label update coupled with the recent 3-year overall survival data continue to reinforce the PACIFIC regimen as the standard of care in this ...

IMFINZI is the only immunotherapy approved to treat patients in this curative-intent setting following chemoradiation therapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca today announced that ...

AstraZeneca Imfinzi label expanded in U.S. for lung cancer Aug. 16, 2024 7:39 AM ET AstraZeneca PLC (AZN) Stock By: Dulan Lokuwithana , SA News Editor 1 Comment Play ( 1min ) ...

AstraZeneca’s Imfinzi already has an FDA approval in the lung cancer maintenance setting under its belt, something none of its rivals will be able to say for a while. And Friday, it hit another ...

References: US Food and Drug Administration. FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer. August 15, 2024.

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib ...

In patients with muscle-invasive bladder cancer, Imfinzi reduced the risk of disease recurring by 32% when given alongside the current standard of care, interim analysis of a late-stage trial found.

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...

Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $2.26 billion in the first half of 2024, up 25% year over year at constant exchange rates.